Organoids for Oncology Drug Screening Services

Organoids are tissue stem cells that have been cultured in vitro. They preserve the original stem cells' stable function by enabling them to proliferate and differentiate further, ultimately forming microorganisms that resemble the source organ in terms of structure, function, genes, and spatial distribution. In order to assess in vitro data with clinically relevant drug potency and efficacy as well as off target consequences, Creative Biolabs provides organoids for oncology drug screening service.

Tumors continue to pose a serious threat to human life and health, despite the fact that tumor treatment has made significant strides in recent years. Early identification and the administration of efficient medications are crucial to the treatment of tumors. The presence of heterogeneity and the complexity of the cancer genome make the treatment effect of the medications used in it less than ideal. Drugs that precisely target tumor cells can be tested for use in medication development without causing harm to normal cells. The stable genomes of several passages, short culture cycles, and great fidelity of organoids give them a significant advantage in drug development and therapeutic guiding. The development of organoids has given rise to a dependable drug-screening platform.

Organoids in drug discovery. (Nie, et al., 2021) Fig.1. Organoids in drug discovery. ¹

Drug Screening using Cancer Organoids

3D Cancer Organoids

More research is being done on the possible application of patient-derived 3D cancer organoids as a better platform for personalized therapy and medication development. These organoid lines demonstrated drug response variability between patients and within tumors, proving that cancer organoids can be a valuable tool for drug screening. Utilizing cancer organoids from four patients, researchers screened 160 medications in a comparatively high-throughput manner. They most likely used 2D culture to screen organoids in order to avoid the laborious procedure of producing 3D organoids. It was revealed that a mere ~5% of the medicines tested exhibited preferred activity in 2D assays as opposed to 3D assays. 2D cell monolayers did not exhibit a correlation between patient-specific genomic modifications and pharmacological effects as reported in organoids, indicating that 3D organoids provide a more accurate physiological model than 2D primary cells.

Cancer Stem-Like Cell Organoids

Early reports of cancer stem-like cells, a tumorigenic population of primary cancer cells that express specific cancer-stem markers, were made in the field of cancer research using tumor spheroid culture. Tumor-derived cancer stem-like cells demonstrated effective spheroid formation and long-term viability in serum-free stem cell media. Cancer cells could be maintained without the Hayflick limit, which was previously believed to be a limit on the long-term culture of primary cancer cells, when they were cultivated in this serum-free stem cell media.

Cancer Tissue-originated Spheroids Organoids

In a nutshell, single cells from the tumor are separated into cancerous ones, which are then collected and allowed to grow into spheroids in matrices or suspension. Nevertheless, single cells isolated from primary tumor tissues are more likely to experience anoikis, a unique type of apoptosis brought on by the lack of anchoring, than established cell lines. The disseminated cells must quickly cling to the plastic surface of the culture plate or become embedded in matrices because anoikis promptly commences upon the separation of tissue or cell clusters. The primary organoid and spheroid production process is more effective when the Rho-ROCK inhibitor is used to suppress anoikis.

Applications of Organoids for Oncology Drug Screening Service

Drug discovery and development
Studies on safety and toxicity
Disease modeling
Possible biomarkers identification

Creative Biolabs offers organoids for oncology drug screening service. We collaborate with you all along the way to make sure the screening goes well. You can modify the procedure to suit your unique requirements. Please contact us for more information.

Reference

Nie, Xialin, et al. "Novel organoid model in drug screening: past, present, and future." Liver Research 5.2 (2021): 72-78.

Note: All of our products are for Research Use Only (RUO). NOT intended for diagnostic, therapeutic or clinical use. We DO NOT offer patients any direct products or services. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.